These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 28952038)

  • 1. Double-Hit Large B Cell Lymphoma.
    Khelfa Y; Lebowicz Y; Jamil MO
    Curr Oncol Rep; 2017 Sep; 19(11):74. PubMed ID: 28952038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular characterization of a rare case of high-grade B-cell lymphoma with MYC, BCL2, BCL6, and CCND1 rearrangements.
    Monika F; Sabri A; Cantu D; Vail E; Siref A
    J Hematop; 2024 Sep; 17(3):155-161. PubMed ID: 38914869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The incidence of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in diffuse large B-cell lymphoma].
    Li M; Zhang QL; Zhao W; Huang X; Gong LP; Shi QF; Liu CL; Gao ZF
    Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):124-128. PubMed ID: 33858042
    [No Abstract]   [Full Text] [Related]  

  • 4. High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study.
    Zayac AS; Landsburg DJ; Hughes ME; Bock AM; Nowakowski GS; Ayers EC; Girton M; Hu M; Beckman AK; Li S; Medeiros LJ; Chang JE; Stepanovic A; Kurt H; Sandoval-Sus J; Ansari-Lari MA; Kothari SK; Kress A; Xu ML; Torka P; Sundaram S; Smith SD; Naresh KN; Karimi YH; Epperla N; Bond DA; Farooq U; Saad M; Evens AM; Pandya K; Naik SG; Kamdar M; Haverkos B; Karmali R; Oh TS; Vose JM; Nutsch H; Rubinstein PG; Chaudhry A; Olszewski AJ
    Blood Adv; 2023 Nov; 7(21):6381-6394. PubMed ID: 37171397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.
    Nowakowski GS; Blum KA; Kahl BS; Friedberg JW; Baizer L; Little RF; Maloney DG; Sehn LH; Williams ME; Wilson WH; Leonard JP; Smith SM
    J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27986884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative genetic alterations of MYC, BCL2, and/or BCL6 in high-grade B-cell lymphoma (HGBL) and diffuse large B-cell lymphoma (DLBCL): Can we identify different prognostic subgroups?
    Blomme S; De Paepe P; Devos H; Emmerechts J; Snauwaert S; Cauwelier B
    Genes Chromosomes Cancer; 2024 Jan; 63(1):e23211. PubMed ID: 37897298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-grade B-cell lymphoma with
    Scott DW; King RL; Staiger AM; Ben-Neriah S; Jiang A; Horn H; Mottok A; Farinha P; Slack GW; Ennishi D; Schmitz N; Pfreundschuh M; Nowakowski GS; Kahl BS; Connors JM; Gascoyne RD; Ott G; Macon WR; Rosenwald A
    Blood; 2018 May; 131(18):2060-2064. PubMed ID: 29475959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potential.
    Zhang C; Stelloo E; Barrans S; Cucco F; Jiang D; Tzioni MM; Chen Z; Li Y; Swennenhuis JF; Makker J; Rásó-Barnett L; Liu H; El-Daly H; Soilleux E; Shah N; Nagumantry SK; Kyaw M; Prahladan MP; Tooze R; Westhead DR; Feitsma H; Davies AJ; Burton C; Johnson PWM; Du MQ
    Leukemia; 2024 Mar; 38(3):621-629. PubMed ID: 38184753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diffuse Large B-Cell Lymphoma Version 1.2016.
    Zelenetz AD; Gordon LI; Wierda WG; Abramson JS; Advani RH; Andreadis CB; Bartlett N; Byrd JC; Fayad LE; Fisher RI; Glenn MJ; Habermann TM; Lee Harris N; Hernandez-Ilizaliturri F; Hoppe RT; Horwitz SM; Kaminski MS; Kelsey CR; Kim YH; Krivacic S; LaCasce AS; Lunning M; Nademanee A; Porcu P; Press O; Rabinovitch R; Reddy N; Reid E; Roberts K; Saad AA; Sokol L; Swinnen LJ; Vose JM; Yahalom J; Zafar N; Dwyer M; Sundar H
    J Natl Compr Canc Netw; 2016 Feb; 14(2):196-231. PubMed ID: 26850490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit.
    Cucco F; Barrans S; Sha C; Clipson A; Crouch S; Dobson R; Chen Z; Thompson JS; Care MA; Cummin T; Caddy J; Liu H; Robinson A; Schuh A; Fitzgibbon J; Painter D; Smith A; Roman E; Tooze R; Burton C; Davies AJ; Westhead DR; Johnson PWM; Du MQ
    Leukemia; 2020 May; 34(5):1329-1341. PubMed ID: 31844144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous presentation of Double Hit Lymphoma: A Case Report With Review of the Literature.
    Khelfa Y; Lebowicz Y
    J Investig Med High Impact Case Rep; 2016; 4(2):2324709616642592. PubMed ID: 27115017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and Clinical Value of MYC , BCL2, and BCL6 Rearrangement Detected by Next-generation Sequencing in DLBCL.
    Zeng Y; Wei R; Bao L; Xue T; Qin Y; Ren M; Bai Q; Yao Q; Yu C; Chen C; Wei P; Yu B; Cao J; Li X; Zhang Q; Zhou X
    Am J Surg Pathol; 2024 Aug; 48(8):919-929. PubMed ID: 38937822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment intensification might not improve survival in high-grade B-cell lymphoma with a concurrent MYC and BCL2 and/or BCL6 rearrangement: A retrospective, multicenter, pooled analysis.
    Zeremski V; McPhail ED; Habermann TM; Schieppati F; Gebauer N; Vassilakopoulos TP; Mougiakakos D
    Hematol Oncol; 2023 Oct; 41(4):776-780. PubMed ID: 36945194
    [No Abstract]   [Full Text] [Related]  

  • 14. Primary cardiac large B cell lymphoma.
    Arun Kumar S; Mishra R; Malempati SC; Bindal P
    BMJ Case Rep; 2023 Dec; 16(12):. PubMed ID: 38151268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting MYC and BCL2 by a natural compound for "double-hit" lymphoma.
    Liu X; Xu S; Zhang J; Fan M; Xie J; Zhang B; Li H; Yu G; Liu Y; Zhang Y; Song J; Horne D; Chan WC; Chu X; Huang W
    Hematol Oncol; 2022 Aug; 40(3):356-369. PubMed ID: 35482553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A MYC-rearrangement is a negative prognostic factor in stage II, but not in stage I diffuse large B-cell lymphoma.
    de Jonge AV; Bult JAA; Karssing DFE; Nijland M; Chamuleau MED; Brink M
    Blood Cancer J; 2024 Jan; 14(1):2. PubMed ID: 38177113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered pathways and targeted therapy in double hit lymphoma.
    Zhuang Y; Che J; Wu M; Guo Y; Xu Y; Dong X; Yang H
    J Hematol Oncol; 2022 Mar; 15(1):26. PubMed ID: 35303910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant.
    Al-Juhaishi T; Wang Y; Milton DR; Xu-Monette ZY; Jabbour E; Daher M; Im JS; Bashir Q; Iyer SP; Marin D; Olson AL; Popat U; Qazilbash M; Rondon G; Gulbis AM; Champlin RE; Young KH; Khouri IF
    Bone Marrow Transplant; 2023 Sep; 58(9):1000-1007. PubMed ID: 37198234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma.
    Green MR; Vicente-Dueñas C; Romero-Camarero I; Long Liu C; Dai B; González-Herrero I; García-Ramírez I; Alonso-Escudero E; Iqbal J; Chan WC; Campos-Sanchez E; Orfao A; Pintado B; Flores T; Blanco O; Jiménez R; Martínez-Climent JA; Criado FJ; Cenador MB; Zhao S; Natkunam Y; Lossos IS; Majeti R; Melnick A; Cobaleda C; Alizadeh AA; Sánchez-García I
    Nat Commun; 2014 Jun; 5():3904. PubMed ID: 24887457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6).
    Witte HM; Riedl J; Künstner A; Fähnrich A; Ketzer J; Fliedner SMJ; Reimer N; Bernard V; von Bubnoff N; Merz H; Busch H; Feller A; Gebauer N
    Target Oncol; 2023 Sep; 18(5):749-765. PubMed ID: 37488307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.